Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9104)	3/11/1999 10:23:00 AM
From: aknahow	Respond to of 17367

Bluegreen are you saying getting enrolled in the trial because you are at or above 8 on the Glasgow scale with a case of meningococcemia, reduces your chance of ..... Or to be more P.C. increases your chances of living? BTW the meeting in Japan is over. My word of advice is: Companies like XOMA, that live in glass houses, should throw parties, serve scones and tell us what happened. "Bio Partnering Asia 8-9, Tokyo, Japan Jack Castello, CEO, Partnering Presentation"

To: Bluegreen who wrote (9104)	3/11/1999 11:27:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Comments on 125 please! My post showed trial based on estimate of 200. My guess is they thought 25% for 100 and 15% for the other 100 producing a target of 40. Yes many other ratios could have been used. But as one will see most logical concepts produce a number close to 40. Many will say that since we don't know how many deaths have already occurred, that the target is of no use. True but this would mean that so far the mortality rate is 39/370 or about 10%. And lets face it they are not just 1 away from the target or they would have waited. So the issue of standard of care is crucial. Do the Brits really have this fantastic system of care that takes scale 8 and higher patients and cures them while they die in the U.S.????